{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T23:31:17Z","timestamp":1782603077528,"version":"3.54.5"},"reference-count":19,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,3,14]],"date-time":"2022-03-14T00:00:00Z","timestamp":1647216000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Surg."],"abstract":"<jats:p>Malignant pleural mesothelioma (MPM) is a rare yet aggressive neoplasm that was linked only to asbestos exposure for decades, although familial clusters were diagnosed with MPM without a known history of asbestos exposure most likely due to genetic susceptibility. Here, we describe a case of familial malignant mesothelioma in a 39 years old patient with a confirmed BAP1 mutation in addition to a known family history with the same mutation. The patient presented with progressive shortness of breath and recurrent pleural effusions and diagnosis was made through biopsies taken during uniportal Video-Assisted Thoracoscopic Surgery. After the inconclusive result of <jats:sup>18<\/jats:sup>F-FDG PET\/CT scan, subxiphoid uniportal Video-Assisted Thoracoscopic Surgery left pleural and laparoscopic peritoneal biopsies were obtained for staging and evaluating contralateral lung and peritoneal cavity. Finally, two important educational values should be acquired from this case: genetic predisposition and BAP1 tumor suppressor gene mutation might affect the age of presentation and overall prognosis of the disease. Also, <jats:sup>18<\/jats:sup>F-FDG PET\/CT scan may not be the best modality for staging and confirming the diagnosis of malignant pleural mesothelioma.<\/jats:p>","DOI":"10.3389\/fsurg.2022.819596","type":"journal-article","created":{"date-parts":[[2022,3,14]],"date-time":"2022-03-14T05:14:20Z","timestamp":1647234860000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Case Report and Review of Literature: Familial Malignant Pleural Mesothelioma in a 39 Years Old Patient With an Inconclusive 18F-FDG PET\/CT Result"],"prefix":"10.3389","volume":"9","author":[{"given":"Mayar","family":"Idkedek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kareem S.","family":"Tahayneh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Firas","family":"Abu-Akar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Izzeddin A.","family":"Bakri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,3,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s12890-018-0619-3","article-title":"Malignant pleural mesothelioma: diagnostic value of medical thoracoscopy and long-term prognostic analysis","volume":"18","author":"Xu","year":"2018","journal-title":"BMC Pulm Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1080\/10937404.2016.1193361","article-title":"Five years update on relationships between malignant pleural mesothelioma and exposure to asbestos and other elongated mineral particles","volume":"19","author":"Andujar","year":"2016","journal-title":"J Toxicol Environ Health B Crit Rev"},{"key":"B3","doi-asserted-by":"publisher","first-page":"S246","DOI":"10.21037\/jtd.2017.10.41","article-title":"The genetic susceptibility in the development of malignant pleural mesothelioma","volume":"10","author":"Melaiu","year":"2018","journal-title":"J Thorac Dis."},{"key":"B4","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1002\/gcc.22670","article-title":"Sensitivity to asbestos is increased in patients with mesothelioma and pathogenic germline variants in BAP1 or other DNA repair genes","volume":"57","author":"Betti","year":"2018","journal-title":"Genes Chromosomes Cancer."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.mrrev.2019.03.001","article-title":"Genetic predisposition for malignant mesothelioma: a concise review","volume":"781","author":"Betti","year":"2019","journal-title":"Mutat Res Rev Mutat Res."},{"key":"B6","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1002\/gcc.22218","article-title":"Inference on germline BAP1 mutations and asbestos exposure from the analysis of familial and sporadic mesothelioma in a high-risk area","volume":"54","author":"Betti","year":"2015","journal-title":"Genes Chromosomes Cancer."},{"key":"B7","unstructured":"Mesothelioma Center-Vital Services for Cancer Patients & Families"},{"key":"B8","unstructured":""},{"key":"B9","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.athoracsur.2017.09.036","article-title":"National trends in the epidemiology of malignant pleural mesothelioma: a national cancer data base study","volume":"105","author":"Saddoughi","year":"2018","journal-title":"Ann Thorac Surg."},{"key":"B10","doi-asserted-by":"publisher","first-page":"127","DOI":"10.2147\/LCTT.S102113","article-title":"Clinical staging of malignant pleural mesothelioma: current perspectives","volume":"8","author":"Bonomi Maria","year":"2017","journal-title":"Lung Cancer."},{"key":"B11","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1510\/icvts.2010.255893","article-title":"What is the best way to diagnose and stage malignant pleural mesothelioma?","volume":"12","author":"Zahid","year":"2011","journal-title":"Interact Cardiovasc Thorac Surg."},{"key":"B12","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1093\/icvts\/ivz303","article-title":"18F-fluorodeoxyglucose positron emission tomography in malignant pleural mesothelioma: diagnostic and prognostic performance and its correlation to pathological results","volume":"30","author":"Lococo","year":"2020","journal-title":"Interact Cardiovasc Thorac Surg"},{"key":"B13","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1007\/s11307-010-0426-6","article-title":"Current evidence base of FDG-PET\/CT imaging in the clinical management of malignant pleural mesothelioma: emerging significance of image segmentation and global disease assessment","volume":"13","author":"Basu","year":"2010","journal-title":"Mol Imaging Biol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"E254","DOI":"10.3978\/j.issn.2072-1439.2013.11.28","article-title":"Guidelines for the diagnosis and treatment of malignant pleural mesothelioma","volume":"5","author":"van Zandwijk","year":"2013","journal-title":"J Thorac Dis."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ejcts\/ezaa158","article-title":"ERS\/ESTS\/EACTS\/ESTRO guidelines for the management of malignant pleural mesothelioma","volume":"58","author":"Opitz","year":"2020","journal-title":"Eur J Cardiothorac Surg."},{"key":"B16","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1093\/carcin\/bgu227","article-title":"Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival","volume":"36","author":"Baumann","year":"2015","journal-title":"Carcinogenesis."},{"key":"B17","doi-asserted-by":"publisher","first-page":"JCO2018790352","DOI":"10.1200\/JCO.2018.79.0352","article-title":"A subset of mesotheliomas with improved survival occurring in carriers of BAP1 and other germline mutations","volume":"36","author":"Pastorino","year":"2018","journal-title":"J Clin Oncol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"543","DOI":"10.21037\/tlcr.2018.07.05","article-title":"The eighth TNM classification for malignant pleural mesothelioma","volume":"7","author":"Berzenji","year":"2018","journal-title":"Transl Lung Cancer Res."},{"key":"B19","doi-asserted-by":"publisher","first-page":"4236","DOI":"10.26355\/eurrev_202106_26129","article-title":"Inherited predisposition to malignant mesothelioma: germline BAP1 mutations and beyond","volume":"25","author":"Pagliuca","year":"2021","journal-title":"Eur Rev Med Pharmacol Sci."}],"container-title":["Frontiers in Surgery"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fsurg.2022.819596\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,14]],"date-time":"2022-03-14T05:14:25Z","timestamp":1647234865000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fsurg.2022.819596\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,14]]},"references-count":19,"alternative-id":["10.3389\/fsurg.2022.819596"],"URL":"https:\/\/doi.org\/10.3389\/fsurg.2022.819596","relation":{},"ISSN":["2296-875X"],"issn-type":[{"value":"2296-875X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,14]]},"article-number":"819596"}}